We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
Read MoreHide Full Article
Key Takeaways
Merck and Daiichi's I-DXd BLA for ES-SCLC wins FDA priority review with Oct. 10, 2026, decision date.
If approved, I-DXd could become the first B7-H3-directed DXd ADC for the given patient population.
MRK and Daiichi's BLA for I-DXd supported by IDeate-Lung01 and IDeate-PanTumor01 studies.
Merck (MRK - Free Report) and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd), a B7-H3-directed DXd antibody-drug conjugate (ADC), for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed on or after platinum-based chemotherapy.
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on Oct. 10, 2026. This status is given to treatments that the FDA believes could significantly improve existing treatment options compared with standard applications.
If approved, I-DXd would become the first-in-class B7-H3-directed DXd ADC for the given patient population.
The FDA is also reviewing the BLA under its Real-Time Oncology Review and Project Orbis initiatives, which aim to speed up access to safe and effective cancer treatments for patients.
The BLA for I-DXd in ES-SCLC was based on data from the phase II IDeate-Lung01 study with support from the phase I/II IDeate-PanTumor01 study.
Year to date, shares of Merck have rallied 14.1% against the industry’s decrease of 2.4%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for I-DXd & Other ADC Candidates
Besides ES-SCLC, I-DXd is being evaluated in separate phase III studies for treating esophageal cancer and prostate cancer. It is also being evaluated in various mid-stage studies for treating certain other types of cancer.
Developed by Daiichi Sankyo, I-DXd already enjoys an orphan drug designation for treating small-cell lung cancer in the United States, Europe and some other countries. Last August, the FDA granted a Breakthrough Therapy designation to I-DXd for treating ES-SCLC in adult patients whose disease progressed on or after platinum-based chemotherapy.
Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August 2024, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Patritumab deruxtecan is being developed in late-stage studies for breast cancer, while raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications.
MRK’s Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
The FDA has also approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer as well as EGFR-mutated non-small-cell lung cancer.
Pfizer (PFE - Free Report) also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023.
Following this acquisition, PFE added four ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2025.
View the Zacks #1 Rank List
Image: Bigstock
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
Key Takeaways
Merck (MRK - Free Report) and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd), a B7-H3-directed DXd antibody-drug conjugate (ADC), for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed on or after platinum-based chemotherapy.
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected on Oct. 10, 2026. This status is given to treatments that the FDA believes could significantly improve existing treatment options compared with standard applications.
If approved, I-DXd would become the first-in-class B7-H3-directed DXd ADC for the given patient population.
The FDA is also reviewing the BLA under its Real-Time Oncology Review and Project Orbis initiatives, which aim to speed up access to safe and effective cancer treatments for patients.
The BLA for I-DXd in ES-SCLC was based on data from the phase II IDeate-Lung01 study with support from the phase I/II IDeate-PanTumor01 study.
Year to date, shares of Merck have rallied 14.1% against the industry’s decrease of 2.4%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for I-DXd & Other ADC Candidates
Besides ES-SCLC, I-DXd is being evaluated in separate phase III studies for treating esophageal cancer and prostate cancer. It is also being evaluated in various mid-stage studies for treating certain other types of cancer.
Developed by Daiichi Sankyo, I-DXd already enjoys an orphan drug designation for treating small-cell lung cancer in the United States, Europe and some other countries. Last August, the FDA granted a Breakthrough Therapy designation to I-DXd for treating ES-SCLC in adult patients whose disease progressed on or after platinum-based chemotherapy.
Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August 2024, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Patritumab deruxtecan is being developed in late-stage studies for breast cancer, while raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications.
MRK’s Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
The FDA has also approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer as well as EGFR-mutated non-small-cell lung cancer.
Pfizer (PFE - Free Report) also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023.
Following this acquisition, PFE added four ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2025.
MRK’s Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.